{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T21:04:47Z","timestamp":1771707887032,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clgc.2026.102505","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:46:07Z","timestamp":1768549567000},"page":"102505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA PET Imaging in the Postradiotherapy Setting: Implications for the Diagnosis of Recurrent Prostate Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-7680","authenticated-orcid":false,"given":"Victoria Vera","family":"Barrag\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves Sicilia","family":"Pozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia Willisch","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alai Go\u00f1i","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miren Gazta\u00f1aga","family":"Boronat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u00edas","family":"Gomis-Sell\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justo Serrano","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"L\u00f3pez Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10231","key":"10.1016\/j.clgc.2026.102505_bib0001","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clgc.2026.102505_bib0002","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2026.102505_bib0003","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00066-017-1239-1","article-title":"Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT for oligometastases in prostate cancer","volume":"194","author":"Baumann","year":"2018","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102505_bib0004","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-020-04945-1","article-title":"False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial","volume":"48","author":"Fendler","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102505_bib0005","first-page":"48","article-title":"PET\/MRI with a ^68Ga-PSMA ligand for the detection of prostate cancer recurrence","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.clgc.2026.102505_bib0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer: report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"issue":"23","key":"10.1016\/j.clgc.2026.102505_bib0007","first-page":"5862","article-title":"Impact of androgen blockade and radiation on PSMA expression: implications for PSMA-targeted imaging and therapy","volume":"26","author":"Hope","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2026.102505_bib0008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","article-title":"Heterogeneous flare in PSMA uptake with initiation of androgen receptor pathway inhibition","volume":"1","author":"Aggarwal","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102505_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920987654","article-title":"Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging","volume":"13","author":"Conteduca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102505_bib0010","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","article-title":"Semiautomatically quantified tumor volume using 68Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer","volume":"61","author":"Seifert","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102505_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110869","article-title":"Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: a single-center retrospective study","volume":"207","author":"Hotta","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clgc.2026.102505_bib0012","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s12149-018-1277-5","article-title":"Prognostic value of 68 Ga PSMA I&T PET\/CT SUV parameters on survival outcome in advanced prostat cancer","volume":"32","author":"Komek","year":"2018","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.clgc.2026.102505_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.879089","article-title":"Correlation between quantitative PSMA PET parameters and clinical risk factors in non-metastatic primary prostate cancer patients","volume":"12","author":"Zschaeck","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102505_bib0014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MNM.0000000000000942","article-title":"Can SUVmax values of Ga-68-PSMA PET\/CT scan predict the clinically significant prostate cancer?","volume":"40","author":"Demirci","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clgc.2026.102505_bib0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13550-020-00730-1","article-title":"The value of 18F-PSMA-1007 PET\/CT in identifying non-metastatic high-risk prostate cancer","volume":"10","author":"Hong","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.clgc.2026.102505_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236841","article-title":"Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients","volume":"15","author":"Zschaeck","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.clgc.2026.102505_bib0017","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13550-017-0333-9","article-title":"Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions","volume":"7","author":"Mei\u00dfner","year":"2017","journal-title":"EJNMMI Res"},{"issue":"13","key":"10.1016\/j.clgc.2026.102505_bib0018","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/cancers17132249","article-title":"Tumor segmentation on PSMA PET\/CT predicts survival in biochemical recurrence of prostate cancer: a retrospective study using [68Ga]Ga-PSMA-11 and [18F]-PSMA-1007","volume":"17","author":"Kudura","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"S1","key":"10.1016\/j.clgc.2026.102505_bib0019","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1038\/modpathol.2017.158","article-title":"Treatment effects in prostate cancer","volume":"31","author":"Evans","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clgc.2026.102505_bib0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5858\/2007-131-360-DOPCAT","article-title":"Diagnosis of prostatic carcinoma after therapy","volume":"131","author":"Bostwick","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clgc.2026.102505_bib0021","first-page":"1617","article-title":"Initial experience with PSMA-PET imaging in prostate cancer patients: correlation with clinical parameters","volume":"44","author":"Schmuck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102505_bib0022","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102505_bib0023","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","article-title":"Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clgc.2026.102505_bib0024","first-page":"1291","article-title":"Diagnostic performance of ^18F-DCFPyL PET\/CT in men with biochemically recurrent prostate cancer (CONDOR)","volume":"39","author":"Morris","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102505_bib0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.semnuclmed.2019.02.006","article-title":"PSMA PET imaging of prostate cancer: an update on pitfalls","volume":"49","author":"Sheikhbahaei","year":"2019","journal-title":"Semin Nucl Med"},{"issue":"8","key":"10.1016\/j.clgc.2026.102505_bib0026","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00259-016-3366-9","article-title":"Detection of recurrent prostate cancer lesions before salvage lymphadenectomy: PSMA vs. fluorocholine PET\/CT","volume":"43","author":"Pfister","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.clgc.2026.102505_bib0027","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2967\/jnumed.116.173492","article-title":"Value of ^68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases compared with histopathology after salvage lymphadenectomy","volume":"57","author":"Rauscher","year":"2016","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.clgc.2026.102505_bib0028","first-page":"584","article-title":"Performance of ^68Ga-PSMA-11 PET for detecting prostate cancer in the lymph nodes before salvage dissection: systematic review and meta-analysis","volume":"22","author":"Kimura","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.clgc.2026.102505_bib0029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41824-024-00212-w","article-title":"PSMA-PET\/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer","volume":"8","author":"Sheikh","year":"2024","journal-title":"EJNMMI Rep"},{"issue":"12","key":"10.1016\/j.clgc.2026.102505_bib0030","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","article-title":"Impact of ^68Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial","volume":"61","author":"Fendler","year":"2020","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.clgc.2026.102505_bib0031","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 PSMA PET in prostate cancer: updated diagnostic utility, sensitivity, specificity, and distribution of PSMA-avid lesions: a systematic review and meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102505_bib0032","first-page":"1291","article-title":"Diagnostic performance of ^18F-DCFPyL PET\/CT in men with biochemically recurrent prostate cancer (CONDOR trial)","volume":"39","author":"Morris","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102505_bib0033","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JU.0000000000000198","article-title":"PSMA-targeted PET tracers for detecting biochemical recurrence after definitive therapy: a systematic review and meta-analysis","volume":"202","author":"Tan","year":"2019","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102505_bib0034","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3390\/cancers17081350","article-title":"Impact of PSMA PET\/CT on radiotherapy treatment decisions in prostate cancer","volume":"17","author":"Gomis-Sell\u00e9s","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2026.102505_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00259-015-3206-3","article-title":"Comparison of PET\/CT and PET\/MRI with ^68Ga-PSMA for evaluation of prostate cancer recurrence","volume":"43","author":"Freitag","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.clgc.2026.102505_bib0036","first-page":"1648","article-title":"Nomograms to predict outcome after ^177Lu-PSMA therapy in patients with mCRPC: importance of dual-tracer imaging (FDG+PSMA)","volume":"62","author":"Gafita","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102505_bib0037","first-page":"214","article-title":"Artificial intelligence-based PET analysis for prostate cancer: diagnostic accuracy and limitations","volume":"49","author":"Schwarzenboeck","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.clgc.2026.102505_bib0038","first-page":"896","article-title":"Nomograms to predict outcome after ^177Lu-PSMA therapy in patients with mCRPC","volume":"62","author":"Gafita","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102505_bib0039","first-page":"1968","article-title":"Asphericity of PSMA-ligand PET\/CT in prostate cancer: a novel biomarker for tumor heterogeneity and patient survival","volume":"47","author":"Seifert","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.clgc.2026.102505_bib0040","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.clgc.2026.102505_bib0041","article-title":"Role of 18F-fluciclovine PET\/CT in patients with biochemical recurrence of prostate cancer and a negative PSMA PET\/CT","volume":"66","author":"Mallak","year":"2025","journal-title":"J Nucl Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:28:44Z","timestamp":1771705724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1558767326000054"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102505","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA PET Imaging in the Postradiotherapy Setting: Implications for the Diagnosis of Recurrent Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102505"}}